Our study also reports that indicators related to NAFLD, including FLI and ALT, are likely to decrease in patients with higher baseline serum C-peptide levels or body fat percentage, which means that patients with higher insulin resistance can benefit from SGLT2-i. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.